• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Turning Point Brands Announces Fourth Quarter and Full Year 2024 Results

    3/6/25 6:30:00 AM ET
    $TPB
    Tobacco
    Consumer Discretionary
    Get the next $TPB alert in real time by email
    • Q4 2024 Adjusted EBITDA of $26.2 million, up 5.3% over prior year
    • Net Sales for Q4 2024 Increased 12.8% Year-Over-Year to $93.7 million
    • FY 2024 Adjusted EBITDA of $104.5 million, up 12.0% over prior year
    • FY 2025 guidance: Adjusted EBITDA of $108-113 million and Modern Oral sales of $60-80 million

    Turning Point Brands, Inc. ("TPB" or "the Company") (NYSE:TPB), a manufacturer, marketer and distributor of branded consumer products, including alternative smoking accessories and consumables with active ingredients, today announced financial results for the fourth quarter and full year ended December 31, 2024.

    Q4 2024 vs. Q4 2023

    • Total consolidated net sales increased 12.8% to $93.7 million
      • Zig-Zag Product Segment net sales increased 1.8%
      • Stoker's Product Segment net sales increased 25.8%
    • Gross profit increased 10.6% to $52.4 million
    • Adjusted EBITDA increased 5.3% to $26.2 million (see Schedule A for a reconciliation to net income)
    • Net income decreased 76.1% to $2.4 million compared to $10.1 million in the year-ago period, driven primarily by a one-time loss from discontinued operations (CDS) of $7.3 million
    • Adjusted net income increased 12.7% to $18.0 million (see Schedule B for a reconciliation to net income)
    • Diluted EPS of $0.13 and Adjusted Diluted EPS of $0.98 compared to $0.53 and $0.82, respectively, in the same period one year ago (see Schedule B for a reconciliation to Diluted EPS)

    FY 2024 vs. FY 2023

    • Total consolidated net sales increased 11.0% to $360.7 million
      • Zig-Zag Product Segment net sales increased 6.6%
      • Stoker's Product Segment net sales increased 16.4%
    • Gross profit increased 10.2% to $201.6 million
    • Adjusted EBITDA increased 12.0% to $104.5 million (see Schedule A for a reconciliation to net income)
    • Net income increased 3.5% to $39.8 million
    • Adjusted net income increased 15.5% to $65.9 million (see Schedule B for a reconciliation to net income)
    • Diluted EPS of $2.14 and Adjusted Diluted EPS of $3.49 compared to $2.01 and $2.93, respectively, in the same period one year ago (see Schedule B for a reconciliation to Diluted EPS)

    Graham Purdy, President and CEO, commented, "We were pleased with our fourth quarter and full year 2024 results and the momentum we are seeing across the organization. We believe Zig-Zag remains on a sustainable growth trajectory with Stoker's MST continuing to grow market share. In Modern Oral, combined sales were $11.2 million for the quarter. FRE sales more than quadrupled versus year-ago and grew 26% sequentially, and we are excited by the successful launch of ALP during the quarter."

    Zig-Zag Products Segment (49% of total net sales in the quarter)

    For the fourth quarter, Zig-Zag Products net sales increased 1.8% to $45.9 million driven by solid performance in our US Papers & Wraps business, partially offset by Clipper. Excluding Clipper, Zig-Zag revenue was up 4.1%.

    For the quarter, the Zig-Zag Products segment gross profit decreased 2.5% to $24.8 million. Gross margin declined 240 basis points to 54.1% driven primarily by product mix.

    For the full year, Zig-Zag Products net sales increased 6.6% to $192.3 million driven by strong performance in our North American Papers & Wraps business and solid growth in cigars that was partially offset by declines in lighter sales.

    For the full year, the Zig-Zag Products segment gross profit increased 5.5% to $106.6 million. Gross margin declined 60 basis points to 55.4% driven primarily by product mix.

    Stoker's Products Segment (51% of total net sales in the quarter)

    For the fourth quarter, Stoker's Products net sales increased 25.8% to $47.8 million, driven by strong growth in our combined Modern Oral sales, partially offset by low-single-digit declines in MST against a strong comp from Q4 2023. For the fourth quarter, total Stoker's Products segment volume increased 17.8%, while price / product mix increased 8.0%.

    For the quarter, the Stoker's Products segment gross profit increased 26.0% to $27.6 million. Gross margin increased 10 basis points to 57.7%

    For the full year, Stoker's Products net sales increased 16.4% to $168.3 million. The segment was driven by triple-digit growth off a low base for our combined Modern Oral business and mid-single-digit growth from MST partially offset by low-single-digit decline in loose-leaf chew. For the year, total Stoker's Products segment volume increased 6.8%, while price / product mix increased 9.6%.

    For the full year, the Stoker's Products segment gross profit increased 16.0% to $95.0 million. Gross margin decreased 20 basis points to 56.4%

    Performance Measures in the Fourth Quarter

    Fourth quarter consolidated selling, general and administrative ("SG&A") expenses were $34.5 million compared to $27.1 million in the fourth quarter of 2023.

    The fourth quarter SG&A included the following notable items:

    • $0.5 million of FDA PMTA-related expenses for modern oral products compared to $1.0 million in the year-ago period
    • $1.1 million of transaction related costs compared to less than $0.1 million in the year-ago period
    • $2.9 million of corporate restructuring costs compared to $0.2 million in the year-ago period

    Total gross debt as of December 31, 2024 was $248.6 million. Net debt (total gross debt less unrestricted cash) as of December 31, 2024 was $202.4 million. The Company ended the quarter with total liquidity of $103.6 million, comprised of $46.2 million in cash and $57.4 million of asset backed revolving credit facility capacity.

    During the quarter, the Company re-purchased 21,072 shares of common stock at a cost of $0.9 million.

    On January 2, 2025, the Company contributed 100% of its interest in South Beach Brands LLC, the subsidiary that owned and operated the Company's former Creative Distribution Solutions reportable segment, to General Wireless Operations, Inc., giving the Company a 49% ownership interest in the joint venture. This business is presented as discontinued operations in the exhibits below.

    Last month, the Company issued $300 million of senior secured notes due 2032 (the "2032 Notes"), the proceeds of which were used to repay its $250 million of existing senior secured notes due 2026 with no pre-payment penalty. The Company is well within its previously disclosed net leverage range of 2 to 3 times and is comfortable with its liquidity position.

    2025 Outlook

    Management expects full-year 2025 adjusted EBITDA to be $108 to $113 million and projects combined Modern Oral sales of $60 to $80 million.

    Earnings Conference Call

    As previously disclosed, a conference call with the investment community to review TPB's financial results has been scheduled for 10:00 a.m. Eastern on Thursday, March 6, 2025. Investment community participants should dial in 10 minutes ahead of time using the toll-free number (800) 715-9871 (international participants should call (646) 307-1963) and follow the audio prompts after typing in the event ID: 6640134. A live listen-only webcast of the call will be available on the Events and Presentations section of the investor relations portion of the Company website (www.turningpointbrands.com). A replay of the webcast will be available on the site two hours following the call.

    Non-GAAP Financial Measures

    In addition to financial measures prepared in accordance with generally accepted accounting principles in the United States (GAAP), this press release includes certain non-GAAP financial measures including EBITDA, Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS and Adjusted Operating Income (Loss). A reconciliation of these non-GAAP financial measures accompanies this release.

    About Turning Point Brands, Inc.

    Turning Point Brands (NYSE:TPB) is a manufacturer, marketer and distributor of branded consumer products including alternative smoking accessories and consumables with active ingredients through its iconic Zig-Zag® and Stoker's® brands. TPB's products are available in more than 220,000 retail outlets in North America, and on sites such as www.zigzag.com. For the latest news and information about TPB and its brands, please visit www.turningpointbrands.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may generally be identified by the use of words such as "anticipate," "believe," "expect," "intend," "plan" and "will" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. As a result, these statements are not guarantees of future performance and actual events may differ materially from those expressed in or suggested by the forward-looking statements. Any forward-looking statement made by TPB in this press release, its reports filed with the Securities and Exchange Commission (the "SEC") and other public statements made from time-to-time speak only as of the date made. New risks and uncertainties come up from time to time, and it is impossible for TPB to predict or identify all such events or how they may affect it. TPB has no obligation, and does not intend, to update any forward-looking statements after the date hereof, except as required by federal securities laws. Factors that could cause these differences include, but are not limited to those included it the Company's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed by the Company with the SEC. These statements constitute the Company's cautionary statements under the Private Securities Litigation Reform Act of 1995.

    Financial Statements Follow on Subsequent Pages

    Turning Point Brands, Inc.
    Consolidated Statements of Income
    (dollars in thousands except share data)
    (unaudited)
    For the year ended December 31,

     

    2024

     

     

    2023

     

    Net sales

    $

    360,660

     

    $

    325,064

     

    Cost of sales

     

    159,095

     

     

    142,122

     

    Gross profit

     

    201,565

     

     

    182,942

     

    Selling, general, and administrative expenses

     

    122,407

     

     

    104,327

     

    Other operating income

     

    (1,674

    )

     

    (4,345

    )

    Operating income

     

    80,832

     

     

    82,960

     

    Interest expense, net

     

    13,983

     

     

    14,645

     

    Investment loss

     

    1,893

     

     

    11,914

     

    Other income

     

    -

     

     

    (4,000

    )

    Gain on extinguishment of debt

     

    -

     

     

    (1,664

    )

    Income from continuing operations before income taxes

     

    64,956

     

     

    62,065

     

    Income tax expense

     

    16,929

     

     

    23,999

     

    Income from continuing operations

     

    48,027

     

     

    38,066

     

    Loss from discontinued operations, net of tax

     

    (7,517

    )

     

    (285

    )

    Consolidated net income

     

    40,510

     

     

    37,781

     

    Net income (loss) attributable to non-controlling interest

     

    701

     

     

    (681

    )

    Net income attributable to Turning Point Brands, Inc.

    $

    39,809

     

    $

    38,462

     

     
    Basic income (loss) per common share:
    Continuing operations

    $

    2.67

     

    $

    2.20

     

    Discontinued operations

     

    (0.43

    )

     

    (0.01

    )

    Basic earnings per share

    $

    2.24

     

    $

    2.19

     

    Diluted income (loss) per common share:
    Continuing operations

    $

    2.53

     

    $

    2.02

     

    Discontinued operations

     

    (0.39

    )

     

    (0.01

    )

    Diluted earnings per share

    $

    2.14

     

    $

    2.01

     

    Weighted average common shares outstanding:
    Basic

     

    17,734,239

     

     

    17,578,270

     

    Diluted

     

    19,362,806

     

     

    20,467,406

     

    Turning Point Brands, Inc.
    Consolidated Statements of Income
    (dollars in thousands except share data)
    (unaudited)
    Three Months Ended December 31,

     

    2024

     

     

    2023

     

    Net sales

    $

    93,667

     

    $

    83,067

     

    Cost of sales

     

    41,249

     

     

    35,687

     

    Gross profit

     

    52,418

     

     

    47,380

     

    Selling, general, and administrative expenses

     

    34,533

     

     

    27,128

     

    Other operating income

     

    -

     

     

    (4,345

    )

    Operating income

     

    17,885

     

     

    24,597

     

    Interest expense, net

     

    3,631

     

     

    2,632

     

    Investment loss

     

    (224

    )

     

    934

     

    Other income

     

    -

     

     

    (4,000

    )

    Gain on extinguishment of debt

     

    -

     

     

    194

     

    Income from continuing operations before income taxes

     

    14,478

     

     

    24,837

     

    Income tax expense

     

    4,118

     

     

    14,492

     

    Income from continuing operations

     

    10,360

     

     

    10,345

     

    Loss from discontinued operations, net of tax

     

    (7,309

    )

     

    (480

    )

    Consolidated net income

     

    3,051

     

     

    9,865

     

    Net income (loss) attributable to non-controlling interest

     

    635

     

     

    (244

    )

    Net income attributable to Turning Point Brands, Inc.

    $

    2,416

     

    $

    10,109

     

     
    Basic income (loss) per common share:
    Continuing operations

    $

    0.55

     

    $

    0.60

     

    Discontinued operations

     

    (0.41

    )

     

    (0.03

    )

    Basic earnings per share

    $

    0.14

     

    $

    0.57

     

    Diluted income (loss) per common share:
    Continuing operations

    $

    0.53

     

    $

    0.56

     

    Discontinued operations

     

    (0.40

    )

     

    (0.03

    )

    Diluted earnings per share

    $

    0.13

     

    $

    0.53

     

    Weighted average common shares outstanding:
    Basic

     

    17,708,460

     

     

    17,604,313

     

    Diluted

     

    18,251,876

     

     

    20,153,157

     

    Turning Point Brands, Inc.
    Consolidated Balance Sheets
    (dollars in thousands except share data)
    (unaudited)
    December 31,
    ASSETS

     

    2024

     

     

    2023

     

    Current assets:
    Cash

    $

    46,158

     

    $

    116,725

     

    Accounts receivable, net of allowances of $66 in 2024 and $78 in 2023

     

    9,624

     

     

    10,002

     

    Inventories, net

     

    96,253

     

     

    91,698

     

    Current assets held for sale

     

    11,470

     

     

    12,267

     

    Other current assets

     

    34,700

     

     

    36,937

     

    Total current assets

     

    198,205

     

     

    267,629

     

    Property, plant, and equipment, net

     

    26,337

     

     

    25,142

     

    Deferred tax assets

     

    995

     

     

    1,468

     

    Right of use assets

     

    11,610

     

     

    11,359

     

    Deferred financing costs, net

     

    1,823

     

     

    2,450

     

    Goodwill

     

    135,932

     

     

    136,250

     

    Other intangible assets, net

     

    65,254

     

     

    66,490

     

    Master Settlement Agreement (MSA) escrow deposits

     

    28,676

     

     

    28,684

     

    Noncurrent assets held for sale

     

    3,859

     

     

    14,731

     

    Other assets

     

    20,662

     

     

    15,166

     

    Total assets

    $

    493,353

     

    $

    569,369

     

     
    LIABILITIES AND STOCKHOLDERS' EQUITY
    Current liabilities:
    Accounts payable

    $

    11,675

     

    $

    7,794

     

    Accrued liabilities

     

    31,096

     

     

    32,052

     

    Current portion of long-term debt

     

    -

     

     

    58,294

     

    Current liabilities held for sale

     

    2,049

     

     

    2,209

     

    Total current liabilities

     

    44,820

     

     

    100,349

     

    Notes payable and long-term debt

     

    248,604

     

     

    307,064

     

    Lease liabilities

     

    9,549

     

     

    9,898

     

    Noncurrent liabilities held for sale

     

    -

     

     

    52

     

    Total liabilities

     

    302,973

     

     

    417,363

     

     
    Commitments and contingencies
     
    Stockholders' equity:
    Preferred stock; $0.01 par value; authorized shares 40,000,000; issued and outstanding shares -0-

     

    -

     

     

    -

     

    Common stock, voting, $0.01 par value; authorized shares, 190,000,000; 20,200,886 issued shares, 17,729,481 outstanding shares at December 31, 2024, and 19,922,137 issued shares, 17,605,677 outstanding shares at December 31, 2023

     

    202

     

     

    199

     

    Common stock, nonvoting, $0.01 par value; authorized shares, 10,000,000; issued and outstanding shares -0-

     

    -

     

     

    -

     

    Additional paid-in capital

     

    126,662

     

     

    119,075

     

    Cost of repurchased common stock (2,471,405 and 2,316,460 shares at December 31, 2024 and 2023)

     

    (83,144

    )

     

    (78,093

    )

    Accumulated other comprehensive loss

     

    (2,903

    )

     

    (2,648

    )

    Accumulated earnings

     

    147,164

     

     

    112,443

     

    Non-controlling interest

     

    2,399

     

     

    1,030

     

    Total stockholders' equity

     

    190,380

     

     

    152,006

     

    Total liabilities and stockholders' equity

    $

    493,353

     

    $

    569,369

     

    Turning Point Brands, Inc.
    Consolidated Statements of Cash Flows
    (dollars in thousands)
    (unaudited)
    For the year ended December 31,

     

    2024

     

     

    2023

     

    Cash flows from operating activities:
    Consolidated net income

    $

    40,510

     

    $

    37,781

     

    Loss from discontinued operations, net of tax

     

    7,517

     

     

    285

     

    Adjustments to reconcile net income to net cash provided by operating activities:
    Gain on extinguishment of debt

     

    -

     

     

    (1,664

    )

    Loss (gain) on sale of property, plant, and equipment

     

    75

     

     

    62

     

    Gain on insurance recovery of inventory loss

     

    -

     

     

    (15,181

    )

    Loss on investments

     

    2,722

     

     

    12,177

     

    Depreciation and other amortization expense

     

    4,439

     

     

    2,921

     

    Amortization of other intangible assets

     

    1,223

     

     

    1,197

     

    Amortization of deferred financing costs

     

    2,430

     

     

    2,445

     

    Deferred income tax (benefit) expense

     

    519

     

     

    7,024

     

    Stock compensation expense

     

    7,243

     

     

    6,561

     

    Noncash lease income

     

    (622

    )

     

    (72

    )

    Gain on MSA investments

     

    (14

    )

     

    -

     

    Changes in operating assets and liabilities:
    Accounts receivable

     

    185

     

     

    (2,625

    )

    Inventories

     

    (4,770

    )

     

    13,287

     

    Other current assets

     

    (1,421

    )

     

    (3,794

    )

    Other assets

     

    (1,767

    )

     

    (4,865

    )

    Accounts payable

     

    3,689

     

     

    100

     

    Accrued liabilities and other

     

    (1,000

    )

     

    601

     

    Operating cash flows from continuing operations

     

    60,958

     

     

    56,240

     

    Operating cash flows from discontinued operations

     

    6,104

     

     

    10,641

     

    Net cash provided by operating activities

    $

    67,062

     

    $

    66,881

     

     
    Cash flows from investing activities:
    Capital expenditures

    $

    (4,623

    )

    $

    (5,707

    )

    Purchases of investments

     

    (10,857

    )

     

    (202

    )

    Proceeds from sale of investments

     

    5,420

     

     

    -

     

    Purchases of non-marketable equity investments

     

    (500

    )

     

    -

     

    Proceeds on sale of property, plant and equipment

     

    5

     

     

    3

     

    MSA escrow deposits, net

     

    46

     

     

    -

     

    Investing cash flows from continuing operations

     

    (10,509

    )

     

    (5,906

    )

    Investing cash flows from discontinued operations

     

    -

     

     

    -

     

    Net cash used in investing activities

    $

    (10,509

    )

    $

    (5,906

    )

     
    Cash flows from financing activities:
    Convertible Senior Notes repurchased

    $

    -

     

    $

    (41,794

    )

    Payment of Convertible Senior Notes

     

    (118,541

    )

     

    -

     

    Proceeds from call options

     

    -

     

     

    114

     

    Payment of dividends

     

    (4,905

    )

     

    (4,497

    )

    Payments of financing costs

     

    (133

    )

     

    (2,437

    )

    Exercise of options

     

    2,807

     

     

    450

     

    Redemption of options

     

    (335

    )

     

    (346

    )

    Redemption of restricted stock units

     

    (914

    )

     

    (995

    )

    Redemption of performance based restricted stock units

     

    (1,212

    )

     

    -

     

    Common stock repurchased

     

    (5,051

    )

     

    -

     

    Financing cash flows from continuing operations

     

    (128,284

    )

     

    (49,505

    )

    Financing cash flows from discontinued operations

     

    -

     

     

    -

     

    Net cash used in financing activities

    $

    (128,284

    )

    $

    (49,505

    )

     
    Net (decrease) increase in cash

    $

    (71,731

    )

    $

    11,470

     

    Effect of foreign currency translation on cash

    $

    (182

    )

    $

    13

     

     
    Cash, beginning of period:
    Unrestricted

    $

    117,886

     

    $

    106,403

     

    Restricted

     

    4,929

     

     

    4,929

     

    Total cash at beginning of period

    $

    122,815

     

    $

    111,332

     

     
    Cash, end of period:
    Unrestricted

    $

    48,941

     

    $

    117,886

     

    Restricted

     

    1,961

     

     

    4,929

     

    Total cash at end of period

    $

    50,902

     

    $

    122,815

     

     

    Non-GAAP Financial Measures

    To supplement our financial information presented in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, we use non-U.S. GAAP financial measures, including EBITDA, Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS, and Adjusted Operating Income (Loss). We believe Adjusted EBITDA provides useful information to management and investors regarding certain financial and business trends relating to our financial condition and results of operations. Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS, and Adjusted Operating Income (Loss) are used by management to compare our performance to that of prior periods for trend analyses and planning purposes and are presented to our board of directors. We believe that EBITDA, Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS, and Adjusted Operating Income (Loss) are appropriate measures of operating performance because they eliminate the impact of expenses that do not relate to business performance.

    We define "EBITDA" as net income before interest expense, gain (loss) on extinguishment of debt, income tax expense, depreciation, amortization. We define "Adjusted EBITDA" as net income before interest expense, gain (loss) on extinguishment of debt, income tax expense, depreciation, amortization, other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define "Adjusted Net Income" as net income excluding items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define "Adjusted Diluted EPS" as diluted earnings per share excluding items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define "Adjusted Operating Income (Loss)" as operating income (loss) excluding other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance.

    Non-U.S. GAAP measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP. EBITDA, Adjusted Net Income, Adjusted EBITDA, Adjusted Diluted EPS, and Adjusted Operating Income (Loss) exclude significant expenses that are required by U.S. GAAP to be recorded in our financial statements and is subject to inherent limitations. In addition, other companies in our industry may calculate this non-U.S. GAAP measure differently than we do or may not calculate it at all, limiting its usefulness as a comparative measure.

    In accordance with SEC rules, we have provided, in the supplemental information attached, a reconciliation of the non-GAAP measures to the next directly comparable GAAP measures.

    Schedule A  
     
    Turning Point Brands, Inc.
    Reconciliation of GAAP Net Income to Adjusted EBITDA
    (dollars in thousands)
    (unaudited)

    For the Year Ended

    December 31,

     

    2024

     

     

    2023

     

    Consolidated net income

    $

    39,809

     

    $

    38,462

     

    Loss from discontinued operations, net of tax

     

    7,517

     

     

    285

     

    Add:
    Interest expense, net

     

    13,983

     

     

    14,645

     

    Gain on extinguishment of debt

     

    -

     

     

    (1,664

    )

    Income tax expense

     

    16,929

     

     

    23,999

     

    Depreciation expense

     

    3,329

     

     

    2,780

     

    Amortization expense

     

    2,333

     

     

    1,338

     

    EBITDA

    $

    83,900

     

    $

    79,845

     

    Components of Adjusted EBITDA
    Corporate restructuring (a)

     

    4,634

     

     

    199

     

    ERP/CRM (b)

     

    993

     

     

    552

     

    Stock based compensation (c)

     

    7,243

     

     

    6,561

     

    Transactional expenses and strategic initiatives (d)

     

    2,107

     

     

    165

     

    FDA PMTA (e)

     

    3,592

     

     

    2,098

     

    Non-cash asset impairment (f)

     

    2,722

     

     

    12,177

     

    FET Refund (g)

     

    (1,674

    )

     

    (4,345

    )

    Legal settlement (h)

     

    -

     

     

    (4,000

    )

    Mark-to-market loss on Canadian inter-company note (i)

     

    942

     

     

    -

     

    Adjusted EBITDA

    $

    104,459

     

    $

    93,252

     

     
     
    (a) Represents costs associated with corporate restructuring, including severance and early retirement
    (b) Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses.
    (c) Represents non-cash stock options, restricted stock, PSRUs, etc.
    (d) Represents the fees incurred for transaction expenses.
    (e) Represents costs associated with applications related to FDA premarket tobacco product application ("PMTA"). The PMTA regime requires the Company to submit an application to the FDA to receive marketing authorization to continue to sell certain of its product lines with continued sales permitted during the pendency of the applications. The application is a onetime resource-intensive process for each covered product line; however, due to the nature of the implementation process for those product lines already in the market, applications can take multiple years to complete rather than the typical one-time submission. The Company currently has only two product lines currently subject to the PMTA process, having utilized other regulatory pathway options available for our other product lines. The Company does not expect to submit additional PMTA applications for any new product lines after the submission for the remaining two are complete.
    (f) Represents impairment of investment assets.
    (g) Represents federal excise tax refund included in other operating income, net.
    (h) Represents other income from litigation settlement.
    (i) Represents a mark-to-market loss attributable to foreign exchange fluctuation.
    Schedule A
     
    Turning Point Brands, Inc.
    Reconciliation of GAAP Net Income to Adjusted EBITDA
    (dollars in thousands)
    (unaudited)

    Three Months Ended

     December 31, 

     

    2024

     

    2023

     

    Consolidated net income

     $

           2,416

     $

       10,109

     

    Loss from discontinued operations, net of tax

     

              7,309

     

               480

     

    Add:
    Interest expense, net

     

              3,631

     

            2,632

     

    Gain on extinguishment of debt

     

                    -  

     

               194

     

    Income tax expense 

     

              4,118

     

          14,492

     

    Depreciation expense

     

                 831

     

               730

     

    Amortization expense

     

                 736

     

               375

     

    EBITDA

     $

         19,041

     $

       29,012

     

    Components of Adjusted EBITDA
    Corporate restructuring (a) 

     

              2,904

     

               199

     

    ERP/CRM (b)

     

                 212

     

               138

     

    Stock based compensation (c)

     

              1,523

     

            1,901

     

    Transactional expenses and strategic initiatives(d)

     

              1,107

     

                   3

     

    FDA PMTA (e)

     

                 512

     

            1,003

     

    Non-cash asset impairment (f)

     

                    -  

     

            1,015

     

    FET refund (g)

     

                    -  

     

          (4,345

    )

    Legal settlement (h)

     

                    -  

     

          (4,000

    )

    Mark-to-market loss on Canadian inter-company note (i)

     

                 942

     

                 -

     

    Adjusted EBITDA

     $

         26,241

     $

       24,926

     

     
           
    (a) Represents costs associated with corporate restructuring, including severance and early retirement
    (b) Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses.
    (c)  Represents non-cash stock options, restricted stock, PSRUs, etc.
    (d) Represents the fees incurred for transaction expenses.
    (e)  Represents costs associated with applications related to FDA premarket tobacco product application ("PMTA").  The PMTA regime requires the Company to submit an application to the FDA to receive marketing authorization to continue to sell certain of its product lines with continued sales permitted during the pendency of the applications. The application is a onetime resource-intensive process for each covered product line; however, due to the nature of the implementation process for those product lines already in the market, applications can take multiple years to complete rather than the typical one-time submission. The Company currently has only two product lines currently subject to the PMTA process, having utilized other regulatory pathway options available for our other product lines. The Company does not expect to submit additional PMTA applications for any new product lines after the submission for the remaining two are complete.
    (f) Represents impairment of investment assets.
    (g) Represents federal excise tax refund included in other operating income, net.
    (h) Represents other income from litigation settlement.
    (i) Represents a mark-to-market loss attributable to foreign exchange fluctuation.
    Schedule B
     
    Turning Point Brands
    Reconciliation of GAAP Net Income to Adjusted Net Income and Diluted EPS to Adjusted Diluted EPS
    (dollars in thousands except share data)
    (unaudited) For the Year Ended For the Year Ended
    December 31, 2024 December 31, 2023

    Income from continuing operations before income taxes

     

    Income tax expense (m)

     

    Loss from discontinued operations, net of tax (o)

    Net loss attributable to non-controlling interest

     

    Adjusted Net Income

     

    Adjusted Diluted EPS

     

    Income from continuing operations before income taxes

     

    Income tax expense (m)

     

    Loss from discontinued operations, net of tax (o)

    Net loss attributable to non-controlling interest

     

    Net Income

     

    Diluted EPS

    GAAP Net Income and Diluted EPS

    $

    64,956

     

    $

    16,929

     

    $

    7,517

     

    $

    701

    $

    39,809

     

    $

    2.14

     

    $

    62,065

     

    $

    23,999

     

    $

    285

     

    $

    (681

    )

    $

    38,462

     

    $

    2.01

     

     
    Loss on discontinued operations (a)

     

    -

     

     

    -

     

     

    (9,970

    )

     

    -

     

    9,970

     

     

    0.51

     

     

    -

     

     

    -

     

     

    (383

    )

     

    -

     

     

    383

     

     

    0.03

     

    Gain on extinguishment of debt (b)

     

    -

     

     

    -

     

     

    -

     

     

    -

     

    -

     

     

    -

     

     

    (1,664

    )

     

    (419

    )

     

    -

     

     

    -

     

     

    (1,245

    )

     

    (0.06

    )

    Corporate restructuring (c)

     

    4,634

     

     

    1,208

     

     

    -

     

     

    -

     

    3,426

     

     

    0.18

     

     

    199

     

     

    50

     

     

    -

     

     

    -

     

     

    149

     

     

    0.01

     

    ERP/CRM (d)

     

    993

     

     

    259

     

     

    -

     

     

    -

     

    734

     

     

    0.04

     

     

    552

     

     

    139

     

     

    -

     

     

    -

     

     

    413

     

     

    0.02

     

    Stock based compensation (e)

     

    7,243

     

     

    1,888

     

     

    -

     

     

    -

     

    5,355

     

     

    0.28

     

     

    6,561

     

     

    1,651

     

     

    -

     

     

    -

     

     

    4,910

     

     

    0.24

     

    Transactional expenses and strategic initiatives (f)

     

    2,107

     

     

    549

     

     

    -

     

     

    -

     

    1,558

     

     

    0.08

     

     

    165

     

     

    42

     

     

    -

     

     

    -

     

     

    123

     

     

    0.01

     

    FDA PMTA (g)

     

    3,592

     

     

    936

     

     

    -

     

     

    -

     

    2,656

     

     

    0.14

     

     

    2,098

     

     

    528

     

     

    -

     

     

    -

     

     

    1,570

     

     

    0.08

     

    Non-cash asset impairment (h)

     

    2,722

     

     

    709

     

     

    -

     

     

    -

     

    2,013

     

     

    0.10

     

     

    12,177

     

     

    3,063

     

     

    -

     

     

    -

     

     

    9,114

     

     

    0.45

     

    FET refund (i)

     

    (1,674

    )

     

    (436

    )

     

    -

     

     

    -

     

    (1,238

    )

     

    (0.06

    )

     

    (5,095

    )

     

    (1,282

    )

     

    -

     

     

    -

     

     

    (3,813

    )

     

    (0.19

    )

    Legal settlement (j)

     

    -

     

     

    -

     

     

    -

     

     

    -

     

    -

     

     

    -

     

     

    (4,000

    )

     

    (1,006

    )

     

    -

     

     

    -

     

     

    (2,994

    )

     

    (0.15

    )

    Mark-to-market loss on Canadian inter-company note (k)

     

    942

     

     

    246

     

     

    -

     

     

    -

     

    696

     

     

    0.04

     

     

    -

     

     

    -

     

     

    -

     

     

    -

     

     

    -

     

     

    -

     

    Deferred tax valuation allowance (l)

     

    -

     

     

    -

     

     

    -

     

     

    -

     

    -

     

     

    -

     

     

    -

     

     

    (8,383

    )

     

    -

     

     

    -

     

     

    8,383

     

     

    0.41

     

    Tax benefit (n)

     

    -

     

     

    (901

    )

     

    -

     

     

    -

     

    901

     

     

    0.05

     

     

    -

     

     

    (1,593

    )

     

    -

     

     

    -

     

     

    1,593

     

     

    0.08

     

    Adjusted Net Income and Adjusted Diluted EPS

    $

    85,515

     

    $

    21,386

     

    $

    (2,453

    )

    $

    701

    $

    65,881

     

    $

    3.49

     

    $

    73,058

     

    $

    16,788

     

    $

    (98

    )

    $

    (681

    )

    $

    57,049

     

    $

    2.93

     

     

     

     

    Totals may not foot due to rounding
     
    (a) Represents loss on discontinued operations.
    (b) Represents gain on extinguishment of debt.
    (c) Represents costs associated with corporate restructuring, including severance and early retirement.
    (d) Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses.
    (e) Represents non-cash stock options, restricted stock, PSRUs, etc.
    (f) Represents the fees incurred for transaction expenses.
    (g) Represents costs associated with applications related to FDA premarket tobacco product application ("PMTA"). The PMTA regime requires the Company to submit an application to the FDA to receive marketing authorization to continue to sell certain of its product lines with continued sales permitted during the pendency of the applications. The application is a onetime resource-intensive process for each covered product line; however, due to the nature of the implementation process for those product lines already in the market, applications can take multiple years to complete rather than the typical one-time submission. The Company currently has only two product lines currently subject to the PMTA process, having utilized other regulatory pathway options available for our other product lines. The Company does not expect to submit additional PMTA applications for any new product lines after the submission for the remaining two are complete.
    (h) Represents impairment of investment assets.
    (i) Represents federal excise tax refund included in other operating income, net.
    (j) Represents other income from litigation settlement.
    (k) Represents a mark-to-market loss attributable to foreign exchange fluctuation.
    (l) Represents deferred tax valuation allowance.
    (m) Income tax expense calculated using the effective tax rate for the year of 26.1% in 2024 and 25.2% in 2023.
    (n) Represents adjustment from annual tax rate to annual projected tax rate of 25% in 2024 and 23% in 2023.
    (o) Tax allocation for discontinued operations excluded from adjusted net income.
     
    Schedule C                      
                           
    Turning Point Brands, Inc.                      
    Reconciliation of GAAP Operating Income to Adjusted Operating Income 
    (dollars in thousands)                      
    (unaudited)                      
      Consolidated   Zig-Zag   Stoker's
      For the Year Ended   For the Year Ended   For the Year Ended   For the Year Ended   For the Year Ended   For the Year Ended
      December 31, 2024   December 31, 2023   December 31, 2024   December 31, 2023   December 31, 2024   December 31, 2023
                           
    Net sales

     $

                     360,660

     

     $

                     325,064

     

     $

                     192,394

     

     $

                     180,455

     

     $

                     168,266

     $

                     144,609

     
    Gross profit

     $

                     201,565

     

     $

                     182,942

     

     $

                     106,585

     

     $

                     101,055

     

     $

                       94,980

     $

                       81,887

     
    Operating income (loss)

     $

                       80,832

     

     $

                       82,960

     

     $

                       66,697

     

     $

                       68,280

     

     $

                       68,272

     $

                       62,208

    Adjustments:
      Transactional expenses and strategic initiatives 

     

                            2,107

     

     

                               165

     

     

                                 -

     

     

                                 -

     

     

                                 -  

     

                                 -  

      FDA PMTA

     

                            3,592

     

     

                            2,098

     

     

                                 -

     

     

                                 -

     

     

                                 -  

     

                                 -  

      Corporate restructuring

     

                            4,634

     

     

                               199

     

     

                                 -

     

     

                                 -

     

     

                                 -  

     

                                 -  

      ERP/CRM

     

                               993

     

     

                               552

     

     

                                 -

     

     

                                 -

     

     

                                 -  

     

                                 -  

      FET refund

     

                          (1,674

    )

     

                          (4,345

    )

     

                          (1,674

    )

     

                          (4,345

    )

     Mark-to-market loss on Canadian inter-company note

     

                               942

     

     

                                 -

     

     

                               942

     

     

                                 -

     

     

                                 -  

     

                                 -  

    Adjusted operating income (loss)

     $

                       91,426

     

     $

                       81,629

     

     $

                       65,965

     

     $

                       63,935

     

     $

                       68,272

     $

                       62,208

    Schedule B
     
    Turning Point Brands
    Reconciliation of GAAP Net Income to Adjusted Net Income and Diluted EPS to Adjusted Diluted EPS
    (dollars in thousands except share data)
    (unaudited) Three Months Ended Three Months Ended
    December 31, 2024 December 31, 2023
    Income from continuing operations before income taxes Income tax expense (m) Loss from discontinued operations, net of tax (o) Net loss attributable to non-controlling interest Adjusted Net Income Adjusted Diluted EPS Income from continuing operations before income taxes Income tax expense (m) Loss from discontinued operations, net of tax (o) Net loss attributable to non-controlling interest Net Income Diluted EPS
    GAAP Net Income and Diluted EPS

    $

    14,478

    $

    4,118

     

    $

    7,309

     

    $

    635

    $

    2,416

    $

    0.13

    $

    24,837

     

    $

    14,492

     

    $

    480

     

    $

    (244

    )

    $

    10,109

     

    $

    0.53

     

     
    Loss on discontinued operations (a)

     

    -

     

    -

     

     

    (9,694

    )

     

    -

     

    9,694

     

    0.53

     

    -

     

     

    -

     

     

    (644

    )

     

    -

     

     

    644

     

     

    0.03

     

    Loss on extinguishment of debt (b)

     

    -

     

    -

     

     

    -

     

     

    -

     

    -

     

    -

     

    194

     

     

    48

     

     

    -

     

     

    -

     

     

    146

     

     

    0.01

     

    Corporate restructuring (c)

     

    2,904

     

    826

     

     

    -

     

     

    -

     

    2,078

     

    0.11

     

    199

     

     

    49

     

     

    -

     

     

    -

     

     

    150

     

     

    0.01

     

    ERP/CRM (d)

     

    212

     

    60

     

     

    -

     

     

    -

     

    152

     

    0.01

     

    138

     

     

    34

     

     

    -

     

     

    -

     

     

    104

     

     

    0.01

     

    Stock based compensation (e)

     

    1,523

     

    433

     

     

    -

     

     

    -

     

    1,090

     

    0.06

     

    1,901

     

     

    467

     

     

    -

     

     

    -

     

     

    1,434

     

     

    0.07

     

    Transactional expenses and strategic initiatives (f)

     

    1,107

     

    315

     

     

    -

     

     

    -

     

    792

     

    0.04

     

    3

     

     

    1

     

     

    -

     

     

    -

     

     

    2

     

     

    0.00

     

    FDA PMTA (g)

     

    512

     

    146

     

     

    -

     

     

    -

     

    366

     

    0.02

     

    1,003

     

     

    246

     

     

    -

     

     

    -

     

     

    757

     

     

    0.04

     

    Non-cash asset impairment (h)

     

    -

     

    -

     

     

    -

     

     

    -

     

    -

     

    -

     

    1,015

     

     

    249

     

     

    -

     

     

    -

     

     

    766

     

     

    0.04

     

    FET refund (i)

     

    -

     

    -

     

     

    -

     

     

    -

     

    -

     

    -

     

    (5,095

    )

     

    (1,252

    )

     

    -

     

     

    -

     

     

    (3,843

    )

     

    (0.19

    )

    Legal settlement (j)

     

    -

     

    -

     

     

    -

     

     

    -

     

    -

     

    -

     

    (4,000

    )

     

    (983

    )

     

    -

     

     

    -

     

     

    (3,017

    )

     

    (0.15

    )

    Mark-to-market loss on Canadian inter-company note (k)

     

    942

     

    268

     

     

    -

     

     

    -

     

    674

     

    0.04

     

    -

     

     

    -

     

     

    -

     

     

    -

     

     

    -

     

     

    -

     

    Deferred tax valuation allowance (l)

     

    -

     

    -

     

     

    -

     

     

    -

     

    -

     

    -

     

    -

     

     

    (8,383

    )

     

    -

     

     

    -

     

     

    8,383

     

     

    0.42

     

    Tax benefit (n)

     

    -

     

    (725

    )

     

    -

     

     

    -

     

    725

     

    0.04

     

    -

     

     

    (326

    )

     

    -

     

     

    -

     

     

    326

     

     

    0.02

     

    Adjusted Net Income and Adjusted Diluted EPS

    $

    21,678

    $

    5,441

     

    $

    (2,385

    )

    $

    635

    $

    17,987

    $

    0.98

    $

    20,195

     

    $

    4,640

     

    $

    (164

    )

    $

    (244

    )

    $

    15,963

     

    $

    0.82

     

     
     
    Totals may not foot due to rounding
     
    (a) Represents loss on discontinued operations.
    (b) Represents gain on extinguishment of debt.
    (c) Represents costs associated with corporate restructuring, including severance and early retirement.
    (d) Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses.
    (e) Represents non-cash stock options, restricted stock, PSRUs, etc.
    (f) Represents the fees incurred for transaction expenses.
    (g) Represents costs associated with applications related to FDA premarket tobacco product application ("PMTA"). The PMTA regime requires the Company to submit an application to the FDA to receive marketing authorization to continue to sell certain of its product lines with continued sales permitted during the pendency of the applications. The application is a onetime resource-intensive process for each covered product line; however, due to the nature of the implementation process for those product lines already in the market, applications can take multiple years to complete rather than the typical one-time submission. The Company currently has only two product lines currently subject to the PMTA process, having utilized other regulatory pathway options available for our other product lines. The Company does not expect to submit additional PMTA applications for any new product lines after the submission for the remaining two are complete.
    (h) Represents impairment of investment assets.
    (i) Represents federal excise tax refund included in other operating income, net.
    (j) Represents other income from litigation settlement.
    (k) Represents a mark-to-market loss attributable to foreign exchange fluctuation.
    (l) Represents deferred tax valuation allowance.
    (m) Income tax expense calculated using the effective tax rate for the quarter of 28.4% in 2024 and 24.6% in 2023.
    (n) Represents adjustment from quarterly tax rate to annual projected tax rate of 25% in 2024 and 23% in 2023.
    (o) Tax allocation for discontinued operations excluded from adjusted net income.
    Schedule C
     
    Turning Point Brands, Inc.
    Reconciliation of GAAP Operating Income to Adjusted Operating Income
    (dollars in thousands)
    (unaudited)
    Consolidated Zig-Zag Stoker's
    Three Months Ended Three Months Ended Three Months Ended Three Months Ended Three Months Ended Three Months Ended
    December 31, 2024 December 31, 2023 December 31, 2024 December 31, 2023 December 31, 2024 December 31, 2023
     
    Net sales

    $

    93,667

    $

    83,067

     

    $

    45,891

    $

    45,092

     

    $

    47,776

    $

    37,975

     
    Gross profit

    $

    52,418

    $

    47,380

     

    $

    24,848

    $

    25,499

     

    $

    27,570

    $

    21,881

     
    Operating income (loss)

    $

    17,885

    $

    24,597

     

    $

    13,059

    $

    20,968

     

    $

    17,852

    $

    16,833

    Adjustments:
    Transactional expenses and strategic initiatives

     

    1,107

     

    3

     

     

    -

     

    -

     

     

    -

     

    -

    FDA PMTA

     

    512

     

    1,003

     

     

    -

     

    -

     

     

    -

     

    -

    Corporate restructuring

     

    2,904

     

    199

     

     

    -

     

    -

     

     

    -

     

    -

    ERP/CRM

     

    212

     

    138

     

     

    -

     

    -

     

     

    -

     

    -

    FET refund

     

    -

     

    (4,345

    )

     

    -

     

    (4,345

    )

     

    -

     

    -

    Mark-to-market loss on Canadian inter-company note

     

    942

     

    -

     

     

    942

     

    -

     

     

    -

     

    -

    Adjusted operating income (loss)

    $

    23,562

    $

    21,595

     

    $

    14,001

    $

    16,623

     

    $

    17,852

    $

    16,833

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250306952780/en/

    Investor Contacts

    Turning Point Brands, Inc.

    [email protected]

    Get the next $TPB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TPB

    DatePrice TargetRatingAnalyst
    3/3/2025$80.00Buy
    Alliance Global Partners
    11/14/2024$65.00Outperform
    Oppenheimer
    9/19/2024$50.00Buy
    ROTH MKM
    6/6/2023$28.00Buy
    The Benchmark Company
    10/10/2022$28.00 → $22.00Overweight → Equal Weight
    Barclays
    More analyst ratings

    $TPB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sr VP Finance & CAO Wigginton Brian sold $265,125 worth of shares (3,500 units at $75.75), decreasing direct ownership by 26% to 10,171 units (SEC Form 4)

      4 - Turning Point Brands, Inc. (0001290677) (Issuer)

      5/9/25 6:29:27 PM ET
      $TPB
      Tobacco
      Consumer Discretionary
    • Director Wexler Lawrence sold $765,600 worth of shares (10,000 units at $76.56), was granted 1,058 shares and covered exercise/tax liability with 1,119 shares, decreasing direct ownership by 3% to 370,186 units (SEC Form 4)

      4 - Turning Point Brands, Inc. (0001290677) (Issuer)

      5/9/25 6:27:42 PM ET
      $TPB
      Tobacco
      Consumer Discretionary
    • Director Diao H.C. Charles was granted 1,058 shares, increasing direct ownership by 10% to 11,804 units (SEC Form 4)

      4 - Turning Point Brands, Inc. (0001290677) (Issuer)

      5/9/25 6:21:35 PM ET
      $TPB
      Tobacco
      Consumer Discretionary

    $TPB
    Leadership Updates

    Live Leadership Updates

    See more
    • Turning Point Brands Appoints Andrew Flynn as Chief Financial Officer

      Turning Point Brands, Inc. ("TPB" or the "Company") (NYSE:TPB), a manufacturer, marketer and distributor of branded consumer products, including alternative smoking accessories and consumables with active ingredients, announced today the appointment Andrew Flynn as the Company's new Chief Financial Officer, effective on or before April 1, 2024. Mr. Flynn is replacing Louie Reformina, who will step down to pursue other opportunities. Prior to joining Turning Point Brands, Mr. Flynn served as the CFO of Connected Cannabis Co. where he was responsible for bringing sustained profitable growth, expanding geographically and recapitalizing the company. In this role Mr. Flynn operationalized and

      3/11/24 7:30:00 AM ET
      $TPB
      Tobacco
      Consumer Discretionary
    • Kaival Brands Appoints James W. Dobbins as Senior Vice President, General Counsel

      GRANT-VALKARIA, Fla., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) ("Kaival Brands," the "Company," or "we"), today announced that it has appointed James W. Dobbins as General Counsel effective December 5, 2023. Barry Hopkins, Executive Chairman of Kaival Brands, said, "James Dobbins has extensive experience advising companies on a breadth of legal matters, and importantly, he also has a deep, relevant understanding of industry business operations, including corporate governance, M&A, international sourcing, and compliance matters. Along with an anticipated reduction in legal expenses, we are thrilled to welcome James to guide and assist our execut

      12/7/23 8:30:00 AM ET
      $KAVL
      $TPB
      Other Consumer Services
      Consumer Discretionary
      Tobacco
    • Kaival Brands Appoints New Chief Executive Officer and Chief Financial Officer

      Former Turning Points Brands executive Thomas Metzler brings decades of finance and operational industry experience to Kaival Brands as its new Chief Financial Officer Current President & Chief Operating Officer Eric Mosser promoted to Chief Executive Officer GRANT-VALKARIA, Fla., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) ("Kaival Brands," the "Company" or "we," "our" or similar terms), a company focused on incubating and commercializing innovative products into mature and dominant brands, with a current focus on the distribution of electronic nicotine delivery systems (ENDS), which are intended for adults 21 and over, today announced the appoi

      8/3/23 8:15:00 AM ET
      $KAVL
      $TPB
      Other Consumer Services
      Consumer Discretionary
      Tobacco

    $TPB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Turning Point Brands Inc.

      SC 13G/A - Turning Point Brands, Inc. (0001290677) (Subject)

      11/14/24 12:37:11 PM ET
      $TPB
      Tobacco
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Turning Point Brands Inc.

      SC 13G/A - Turning Point Brands, Inc. (0001290677) (Subject)

      11/8/24 4:32:30 PM ET
      $TPB
      Tobacco
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Turning Point Brands Inc.

      SC 13G/A - Turning Point Brands, Inc. (0001290677) (Subject)

      11/8/24 12:58:51 PM ET
      $TPB
      Tobacco
      Consumer Discretionary

    $TPB
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • What Does the Recent Purchase at Turning Point Brands Inc. on Jun 18 Indicate?

      On June 18, 2024, Turning Point Brands Inc. experienced a significant insider purchase when Chief Strategy Officer De Plano Lorenzo bought $127,200 worth of shares. This transaction involved the acquisition of 4,000 units at a price of $31.80 per unit, leading to an increase in his direct ownership by 13% to 34,896 units, as reported in the SEC Form 4. This move by an insider to increase their stake in the company is generally viewed as a positive signal by the market. Examining the recent insider activity at Turning Point Brands Inc., we can identify a few notable trades that occurred around the same time. On May 10, 2024, New insider Catsimatidis John A. Jr claimed ownership of 410,000 sh

      6/18/24 10:08:05 PM ET
      $TPB
      Tobacco
      Consumer Discretionary

    $TPB
    SEC Filings

    See more
    • Turning Point Brands Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Turning Point Brands, Inc. (0001290677) (Filer)

      5/9/25 5:03:09 PM ET
      $TPB
      Tobacco
      Consumer Discretionary
    • SEC Form 10-Q filed by Turning Point Brands Inc.

      10-Q - Turning Point Brands, Inc. (0001290677) (Filer)

      5/7/25 5:28:40 PM ET
      $TPB
      Tobacco
      Consumer Discretionary
    • Turning Point Brands Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Turning Point Brands, Inc. (0001290677) (Filer)

      5/7/25 8:13:12 AM ET
      $TPB
      Tobacco
      Consumer Discretionary

    $TPB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Strategy Officer De Plano Lorenzo bought $127,200 worth of shares (4,000 units at $31.80), increasing direct ownership by 13% to 34,896 units (SEC Form 4)

      4 - Turning Point Brands, Inc. (0001290677) (Issuer)

      6/18/24 5:01:10 PM ET
      $TPB
      Tobacco
      Consumer Discretionary
    • Chief Revenue Officer Frein Summer bought $69,970 worth of shares (2,260 units at $30.96), increasing direct ownership by 15% to 17,203 units (SEC Form 4)

      4 - Turning Point Brands, Inc. (0001290677) (Issuer)

      6/14/24 6:50:56 PM ET
      $TPB
      Tobacco
      Consumer Discretionary
    • De Plano Lorenzo bought $420,753 worth of shares (15,043 units at $27.97), increasing direct ownership by 92% to 31,375 units (SEC Form 4)

      4 - Turning Point Brands, Inc. (0001290677) (Issuer)

      3/18/24 9:17:02 AM ET
      $TPB
      Tobacco
      Consumer Discretionary

    $TPB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Turning Point Brands Declares Common Stock Dividend

      The Board of Directors of Turning Point Brands, Inc. ("TPB") (NYSE:TPB), a manufacturer, marketer and distributor of branded consumer products including alternative smoking accessories and consumables with active ingredients, declared a regular quarterly dividend of $0.075 per common share. The dividend is payable on July 11, 2025, to shareholders of record on the close of business on June 20, 2025. About Turning Point Brands, Inc. Turning Point Brands (NYSE:TPB) is a manufacturer, marketer and distributor of branded consumer products including alternative smoking accessories and consumables with active ingredients through its iconic Zig-Zag®, Stoker's®, FRE®, and ALP® brands. TPB's produ

      5/7/25 4:20:00 PM ET
      $TPB
      Tobacco
      Consumer Discretionary
    • Turning Point Brands Announces First Quarter 2025 Results

      Net Sales for Q1 2025 Increased 28.1% Year-Over-Year to $106.4 million Modern Oral Net Sales for Q1 2025 of $22.3 million Q1 2025 Adjusted EBITDA of $27.7 million, up 12.0% over prior year Reaffirm our previously announced 2025 Adjusted EBITDA guidance of $108.0 – 113.0 million; increasing full-year consolidated nicotine pouch sales guidance to a range of $80.0 – 95.0 million, from $60.0 – 80.0 million Turning Point Brands, Inc. ("TPB" or "the Company") (NYSE:TPB), a manufacturer, marketer and distributor of branded consumer products, including alternative smoking accessories and consumables with active ingredients, today announced financial results for the first quarter ended Marc

      5/7/25 6:30:00 AM ET
      $TPB
      Tobacco
      Consumer Discretionary
    • ALP and Gopuff Launch First of a Kind "Instant Delivery" Partnership

      ALP has officially partnered with Gopuff to launch a new instant delivery feature via ALP's website. ALP Supply Co. will be using Gopuff's new "Powered by Gopuff" technology to help ALP customers get D2C orders faster than ever before. After a wildly successful launch, Tucker Carlson's ALP will now offer customers the ability to order ALP's nicotine pouches and get them delivered almost instantly through Alppouch.com's "Instant Shop," which leverages Gopuff's 200+ micro distribution centers across the United States. "Our new partnership with Gopuff is designed to put the customer first and to make ALP accessible to more adult American consumers than ever before," said ALP Co-Founder Tucke

      5/6/25 2:00:00 PM ET
      $TPB
      Tobacco
      Consumer Discretionary

    $TPB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alliance Global Partners initiated coverage on Turning Point Brands with a new price target

      Alliance Global Partners initiated coverage of Turning Point Brands with a rating of Buy and set a new price target of $80.00

      3/3/25 8:28:08 AM ET
      $TPB
      Tobacco
      Consumer Discretionary
    • Oppenheimer initiated coverage on Turning Point Brands with a new price target

      Oppenheimer initiated coverage of Turning Point Brands with a rating of Outperform and set a new price target of $65.00

      11/14/24 7:57:59 AM ET
      $TPB
      Tobacco
      Consumer Discretionary
    • ROTH MKM initiated coverage on Turning Point Brands with a new price target

      ROTH MKM initiated coverage of Turning Point Brands with a rating of Buy and set a new price target of $50.00

      9/19/24 7:53:13 AM ET
      $TPB
      Tobacco
      Consumer Discretionary

    $TPB
    Financials

    Live finance-specific insights

    See more
    • Turning Point Brands Declares Common Stock Dividend

      The Board of Directors of Turning Point Brands, Inc. ("TPB") (NYSE:TPB), a manufacturer, marketer and distributor of branded consumer products including alternative smoking accessories and consumables with active ingredients, declared a regular quarterly dividend of $0.075 per common share. The dividend is payable on July 11, 2025, to shareholders of record on the close of business on June 20, 2025. About Turning Point Brands, Inc. Turning Point Brands (NYSE:TPB) is a manufacturer, marketer and distributor of branded consumer products including alternative smoking accessories and consumables with active ingredients through its iconic Zig-Zag®, Stoker's®, FRE®, and ALP® brands. TPB's produ

      5/7/25 4:20:00 PM ET
      $TPB
      Tobacco
      Consumer Discretionary
    • Turning Point Brands Announces First Quarter 2025 Results

      Net Sales for Q1 2025 Increased 28.1% Year-Over-Year to $106.4 million Modern Oral Net Sales for Q1 2025 of $22.3 million Q1 2025 Adjusted EBITDA of $27.7 million, up 12.0% over prior year Reaffirm our previously announced 2025 Adjusted EBITDA guidance of $108.0 – 113.0 million; increasing full-year consolidated nicotine pouch sales guidance to a range of $80.0 – 95.0 million, from $60.0 – 80.0 million Turning Point Brands, Inc. ("TPB" or "the Company") (NYSE:TPB), a manufacturer, marketer and distributor of branded consumer products, including alternative smoking accessories and consumables with active ingredients, today announced financial results for the first quarter ended Marc

      5/7/25 6:30:00 AM ET
      $TPB
      Tobacco
      Consumer Discretionary
    • Turning Point Brands to Host Q1 Conference Call

      Turning Point Brands, Inc. (NYSE:TPB) announced the date and time for its conference call to review 1st quarter 2025 results. The conference call will be on Wednesday, May 7, 2025 at 9:30 a.m. Eastern. Interested analysts and professional investors can register and participate through one of these call-in numbers: (800) 715-9871 (U.S., toll-free) (646) 307-1963 (International) Event ID: 6640134 Participants should dial in at least 10 minutes in advance and follow the audio prompts after typing in the Event ID. The call will also be broadcast live as a listen-only webcast from the investor relations section of the company's website at http://www.turningpointbrands.com/investor-relations/e

      4/23/25 5:00:00 PM ET
      $TPB
      Tobacco
      Consumer Discretionary